Evidence map›Paper›PMID 33326807›Full record

ArticleChest2021

Quantitative Emphysema on Low-Dose CT Imaging of the Chest and Risk of Lung Cancer and Airflow Obstruction: An Analysis of the National Lung Screening Trial.

Wassim W Labaki, Meng Xia, Susan Murray, Charles R Hatt, Abdullah Al-Abcha, Michael C Ferrera, Catherine A Meldrum, Lauren A Keith, Craig J Galbán, Douglas A Arenberg and 4 more

Open access · greenAbstract read
In one paragraph

Article in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. COPD-Lung Cancer Comorbidity: Mechanistic Insights and Precision Oncology Implications.International journal of chronic obstructive pulmonary disease · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Lung NR3C1Communications biology · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Wassim W LabakiDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI.
Meng XiaDepartment of Biostatistics, University of Michigan, Ann Arbor, MI.
Susan MurrayDepartment of Biostatistics, University of Michigan, Ann Arbor, MI.
Charles R HattImbio LLC, Minneapolis, MN.
Abdullah Al-AbchaDepartment of Internal Medicine, Michigan State University, East Lansing, MI.
Michael C FerreraDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI.
Catherine A MeldrumDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI.
Lauren A KeithImbio LLC, Minneapolis, MN.
Craig J GalbánDepartment of Radiology, University of Michigan, Ann Arbor, MI.
Douglas A ArenbergDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI.
Jeffrey L CurtisDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI; Medical Service, VA Ann Arbor Healthcare System, Ann Arbor, MI.
Fernando J MartinezDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI; Division of Pulmonary and Critical Care Medicine, Weill Cornell Medical College, New York, NY.
Ella A KazerooniDepartment of Radiology, University of Michigan, Ann Arbor, MI.
MeiLan K HanDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI. Electronic address: mrking@med.umich.edu.
University of Michigan–Ann Arbor · USImbio (United States) · USMichigan State University · USVA Ann Arbor Healthcare System · US

Funding

PULMONARY CELLULAR AND MOLECULAR BIOLOGY TRAININGT32HL007749 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Pickett Dickson · 1993 to 2026
$19.9M
An Early Imaging Marker of EmphysemaR01HL139690 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GALBAN, CRAIG J · 2019 to 2022
$1.9M
Personalized Smoking Cessation Tool Based on Patient Lung CT ImageR44CA203050 · NCI · IMBIO, LLC · PI KEITH, LAUREN, LANDO, HARRY ALAN · 2016 to 2018
$1.5M
Defining Pathways in COPD Patient Oriented ResearchK24HL138188 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MeiLan K Han · 2017 to 2026
$1.2M
NCI NIH HHS R44 CA203050NHLBI NIH HHS K24 HL138188NHLBI NIH HHS R01 HL139690NHLBI NIH HHS T32 HL007749
6 · The paper itself

Abstract

backgroundLung cancer risk prediction models do not routinely incorporate imaging metrics available on low-dose CT (LDCT) imaging of the chest ordered for lung cancer screening. RESEARCH QUESTION: What is the association between quantitative emphysema measured on LDCT imaging and lung cancer incidence and mortality, all-cause mortality, and airflow obstruction in individuals who currently or formerly smoked and are undergoing lung cancer screening? STUDY DESIGN AND

methodsIn 7,262 participants in the CT arm of the National Lung Screening Trial, percent low attenuation area (%LAA) was defined as the percentage of lung volume with voxels less than -950 Hounsfield units on the baseline examination. Multivariable Cox proportional hazards models, adjusting for competing risks where appropriate, were built to test for association between %LAA and lung cancer incidence, lung cancer mortality, and all-cause mortality with censoring at 6 years. In addition, multivariable logistic regression models were built to test the cross-sectional association between %LAA and airflow obstruction on spirometry, which was available in 2,700 participants.

resultsThe median %LAA was 0.8% (interquartile range, 0.2%-2.7%). Every 1% increase in %LAA was independently associated with higher hazards of lung cancer incidence (hazard ratio [HR], 1.02; 95% CI, 1.01-1.03; P = .004), lung cancer mortality (HR, 1.02; 95% CI, 1.00-1.05; P = .045), and all-cause mortality (HR, 1.01; 95% CI, 1.00-1.03; P = .042). Among participants with spirometry, 892 had airflow obstruction. The likelihood of airflow obstruction increased with every 1% increase in %LAA (odds ratio, 1.07; 95% CI, 1.06-1.09; P < .001). A %LAA cutoff of 1% had the best discriminative accuracy for airflow obstruction in participants aged > 65 years.

interpretationQuantitative emphysema measured on LDCT imaging of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked and are undergoing lung cancer screening.

Indexed as

Airway ObstructionCause of DeathEarly Detection of CancerFemaleHumansIncidenceLung NeoplasmsMaleMass ScreeningMiddle AgedPulmonary EmphysemaSmokersTomography, X-Ray ComputedUnited Stateschest imagingCOPDemphysemalung cancer

Identifiers

PMID33326807
PMCPMC8129730
OpenAlexW3112924817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.